Clinical Pharmacy Program Guidelines for Topical Androgens

<table>
<thead>
<tr>
<th>Program</th>
<th>Prior Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication</td>
<td>Preferred product: Testosterone (T gel and pump)</td>
</tr>
<tr>
<td></td>
<td>Non-preferred products: Androderm (testosterone [T] patch), Androgel (T gel and pump), Axiron (T topical solution), Fortesta (T gel), Natesto (T nasal gel), Striant (T buccal system), Testim (T gel), and Vogelxo (T gel and pump)</td>
</tr>
</tbody>
</table>

| Issue Date   | 9/2009 |
| Pharmacy and Therapeutics Approval Date | 3/2017 |
| Effective Date | 5/1/2017 |

1. **Background:**

The topical testosterone products are approved by the Food and Drug Administration (FDA) for testosterone replacement therapy in males with primary hypogonadism (congenital or acquired) or hypogonadotrophic hypogonadism (congenital or acquired). Primary hypogonadism originates from a deficiency or disorder in the testicles. Secondary hypogonadism indicates a problem in the hypothalamus or the pituitary gland. When hypogonadism develops before the age of puberty some of the signs and symptoms of hypogonadism include: small testes, phallus, or prostate, impaired body hair growth, gynecomastia, persistent high pitched voice, and disproportionate growth of arms and legs in comparison to trunk of body. Signs and symptoms associated with later onset hypogonadism are loss of libido, erectile dysfunction, sarcopenia, low bone mass, decreases in muscle mass, depressive thoughts, fatigue, loss of body hair, hot flushes, loss of vigour (1). Testosterone use has been strongly linked to improvements in muscle mass, bone density, and libido (2). Topical products include Axiron, Androderm, Androgel, Fortesta, Natesto, Striant, Testim, and Vogelxo.

The purpose of this program is to provide coverage for androgens and anabolic steroid therapy for the treatment of conditions for which they have shown to be effective and are within the scope of the plan’s drug benefit. Coverage for the enhancement of athletic performance or body building will not be provided.

*Coverage for patient population may be dependent upon benefit design

2. **Coverage Criteria:**
A. **Initial Authorization for Male Patients**

1. **One** of the following:

   a. **Two** pre-treatment serum total testosterone levels less than 280 ng/dL (<9.7 nmol/L) or less than the reference range for the lab, taken at separate times (This may require treatment to be temporarily held. Document lab value and date for both levels) [1]

   **-OR-**

   b. **Both** of the following: [25]

      (1) Patient has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity)

      (2) **One** pre-treatment calculated free or bioavailable testosterone level less than 50 pg/mL (<5 ng/dL or < 0.17 nmol/L) or less than the reference range for the lab (This may require treatment to be temporarily held. Document lab value and date)

   **-OR-**

   c. Patient has a history of **one** of the following:

      (1) Bilateral orchiectomy

      (2) Panhypopituitarism

      (3) A genetic disorder known to cause hypogonadism (eg, congenital anorchia, Klinefelter’s syndrome)

   **-AND-**

2. Patient is **not** taking any of the following:

   a. One of the following growth hormones, unless diagnosed with panhypopituitarism: Genotropin, Humatrope, Norditropin FlexPro, Norditropin NordiFlex, Nutropin, Nutropin AQ, Omnitrope, Saizen, Tev-Tropin [5]

   b. Aromatase inhibitor (eg, Arimidex [anastrozole], Femara [letrazole], Aromasin [exemestane]) [2-5]

   **-AND-**

3. Male patient
4. Diagnosis of hypogonadism

5. One of the following: [11-26]
   a. Significant reduction in weight (less than 90% ideal body weight) (e.g., AIDS wasting syndrome)
   b. Osteopenia
   c. Osteoporosis
   d. Decreased bone density
   e. Decreased libido
   f. Organic cause of testosterone deficiency (e.g., injury, tumor, infection, or genetic defects)

6. If the request is for a non-preferred product, the patient has a history of failure, contraindication, or intolerance to generic testosterone 1% topical gel

   **Patients new to any topical testosterone therapy: Authorization will be issued for 12 months. [25]**
   **Patients continuing testosterone therapy: Authorization will be issued for 12 months.**

B. **Initial Authorization for Female to Male Transsexual Persons** [36]

1. Using hormones to change physical characteristics

2. Demonstrable knowledge of what hormones medically can and cannot do and their social benefits and risks

3. If significant medical or mental health concerns are present, they are reasonably well controlled
4. The covered person must be diagnosed with gender dysphoria, as defined by the current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM) 

-AND-

5. Patient is **not** taking any of the following:

   a. One of the following growth hormones, unless diagnosed with panyhypopituitarism: Genotropin, Humatrope, Norditropin FlexPro, Norditropin NordiFlex, Nutropin, Nutropin AQ, Omnitrope, Saizen, Tev-Tropin [5]

   b. Aromatase inhibitor (eg, Arimidex [anastrozole], Femara [letrozole], Aromasin [exemestane]) [2-5]

-AND-

6. If the request is for a non-preferred product, the patient has a history of failure, contraindication, or intolerance to generic testosterone 1% topical gel

**Patients new to any topical testosterone therapy: Authorization will be issued for 12 months. [25]**

**Patients continuing testosterone therapy: Authorization will be issued for 12 months.**

C. **Reauthorization (non-gender dysphoria)**

1. Reauthorization will be approved based on **both** of the following:

   a. **One** of the following:

      (1) Follow-up total serum testosterone level drawn within the past 12 months is within or below the normal limits of the reporting lab (document value and date)

      -OR-

      (2) Follow-up total serum testosterone level drawn within the past 12 months is outside of upper limits of normal for the reporting lab and the dose is adjusted (document value and date)

      -OR-
(3) Both of the following:

(a) Patient has a condition that may cause altered sex-hormone binding globulin (SHBG) (e.g., thyroid disorder, HIV disease, liver disorder, diabetes, obesity)

-AND-

(b) One of the following:

i. Follow-up calculated free or bioavailable testosterone level drawn within the past 12 months is within or below the normal limits of the reporting lab (document lab value and date)

-OR-

ii. Follow-up calculated free or bioavailable testosterone level drawn within the past 12 months is outside of upper limits of normal for the reporting lab and the dose is adjusted (document value and date)

-AND-

b. Patient is not taking any of the following:

(1) One of the following growth hormones, unless diagnosed with panyhypopituitarism: Genotropin, Humatrope, Norditropin FlexPro, Norditropin NordiFlex, Nutropin, Nutropin AQ, Omnitrope, Saizen, Tev-Tropin [5]

(2) Aromatase inhibitor (eg, Arimidex [anastrozole], Femara [letrozole], Aromasin [exemestane]) [2-5]

Authorization will be issued for 12 months.

3. Additional Clinical Rules:

- Supply limits may be in place.

4. References:

1. AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and


Confidential and Proprietary, © 2017 UnitedHealthcare Services Inc.
<table>
<thead>
<tr>
<th>Date</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept 2009</td>
<td>Criteria taken from previously approved AmeriChoice policy. Policy was reformatted.</td>
</tr>
<tr>
<td>Dec 2010</td>
<td>Annual Review</td>
</tr>
<tr>
<td>March 2011</td>
<td>Annual Review. Added Axiron and Fortesta to non-preferred product list</td>
</tr>
<tr>
<td>Sept 2011</td>
<td>Annual Review. Added Androgel 1.62% to non-preferred product list</td>
</tr>
<tr>
<td>December 2011</td>
<td>Changed Androgel 1.62% from non-preferred product list to preferred product list.</td>
</tr>
<tr>
<td></td>
<td>Changed Androgel 1% from preferred product list to non-preferred product list.</td>
</tr>
<tr>
<td>December 2012</td>
<td>Annual Review</td>
</tr>
<tr>
<td>December 2014</td>
<td>Full updated made to clinical criteria.</td>
</tr>
<tr>
<td></td>
<td>Serum testosterone requirement changed to two levels less than 280 ng/dL, previously required one level less or equal to 300 ng/dL</td>
</tr>
<tr>
<td></td>
<td>Added an alternative diagnostic option to serum testosterone testing: conditions that may cause altered sex-hormone binding globulin with one of the following (1) calculated free or bioavailable testosterone level less than 5 ng/dL or bilateral orchiectomy, panhypopituitarism, or (2) a genetic disorder known to cause hypogonadism.</td>
</tr>
<tr>
<td></td>
<td>Added all of the following new requirements:</td>
</tr>
<tr>
<td></td>
<td>• Not used in combination with growth hormones or aromatase inhibitors</td>
</tr>
<tr>
<td></td>
<td>• Patient is male</td>
</tr>
<tr>
<td></td>
<td>• Diagnosis of hypogonadism</td>
</tr>
<tr>
<td></td>
<td>• One of the following: significant reduction in weight (less than 90% ideal body weight) (eg, AIDS wasting syndrome), osteopenia, osteoporosis, decreased bone density, decreased libido, organic cause of testosterone deficiency</td>
</tr>
<tr>
<td>March 2015</td>
<td>Gender Identity disorder initial criteria created for New Jersey and Washington plans due to plan requirement.</td>
</tr>
<tr>
<td></td>
<td>Gender Identity disorder added to Male hypogonadism reauthorization criteria for New Jersey and Washington plans due to plan requirement.</td>
</tr>
<tr>
<td>Date</td>
<td>Changes</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>June 2015</td>
<td>Changed products that the criteria applies to due to a PDL change.</td>
</tr>
<tr>
<td>November 2016</td>
<td>Updated clinical criteria to align with E&amp;I’s policy, added trial/failure of generic testosterone 1% topical gel to section A and B</td>
</tr>
<tr>
<td>February 2017</td>
<td>Updated header to define preferred and non-preferred products.</td>
</tr>
<tr>
<td></td>
<td>Clarified that reauthorization is for non-gender dysphoria indications.</td>
</tr>
<tr>
<td>March 2017</td>
<td>Changed authorization durations to 12 months.</td>
</tr>
<tr>
<td>April 2017</td>
<td>In the female to male transition section, removed language requiring documented real life experience living as the other gender or a period of psychotherapy as this is not supported by WPATH guidelines.</td>
</tr>
</tbody>
</table>